Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop.
Salerno
R A
RA
Worldwide Regulatory Affairs, Pharma & Translational Medicine, Wyeth Research, Collegeville, PA 19454, USA. salernr@wyeth.com
Lesko
L J
LJ
D015195:Drug Design; D004345:Drug Industry / Q000592:standards / Q000639:trends; D005819:Genetic Markers; D010597:Pharmacogenetics / Q000592:standards / Q000639:trends; D018570:Risk Assessment; D014481:United States; D014486:United States Food and Drug Administration
D005819:Genetic Markers